Cart
sales@molnova.com
RBC8
CAS No. 361185-42-4
RBC8( RBC8 | RBC-8 | RBC 8 )
Catalog No. M17494 CAS No. 361185-42-4
RBC8 is a specific GTPases RalA/RalB inhibitor by inhibiting the binding of Ral to its effector RALBP1, no inhibition on the GTPases RhoA and Ras.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 93 | In Stock |
|
| 5MG | 88 | In Stock |
|
| 10MG | 150 | In Stock |
|
| 25MG | 297 | In Stock |
|
| 50MG | 461 | In Stock |
|
| 100MG | 672 | In Stock |
|
| 200MG | 918 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRBC8
-
NoteResearch use only, not for human use.
-
Brief DescriptionRBC8 is a specific GTPases RalA/RalB inhibitor by inhibiting the binding of Ral to its effector RALBP1, no inhibition on the GTPases RhoA and Ras.
-
DescriptionRBC8 is a RalA and RalB GTPase inhibitor (EC50 ~3.5 μM). RBC8 suppresses growth of xenograft tumors in mice. e Ras-like GTPases RalA and RalB are important drivers of tumour growth and metastasis. Chemicals that block Ral function would be valuable as research tools and for cancer therapeutics.
-
In Vitro——
-
In Vivo——
-
SynonymsRBC8 | RBC-8 | RBC 8
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorGTPases RalA| GTPases RalB
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number361185-42-4
-
Formula Weight424.45
-
Molecular FormulaC25H20N4O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 40 mg/mL; 94.24 mM
-
SMILESCOc1ccc(c(c1)C1C(=C(N)Oc2c1c(c1ccc3ccccc3c1)[nH]n2)C#N)OC
-
Chemical Name6-Amino-4-(2,5-dimethoxyphenyl)-1,4-dihydro-3-(2-naphthalenyl)pyrano[2,3-c]pyrazole-5-carbonitrile
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yan C, et al. Nature. 2014, 515(7527), 443-447.
molnova catalog
related products
-
ML165
A high-affinity, selective platelet integrin αIIbβ3 receptor antagonist with IC50 of 96 nM.
-
SF0166
SF0166 is a topically administered αvβ3 integrin antagonist, inhibits integrin-ligand interactions with IC50 of 0.6 nM to 13 nM for human αvβ3, αvβ6, and αvβ8.
-
α2β1 Integrin Ligand...
The Asp-Gly-Glu-Ala (DGEA) amino acid domain of type I collagen interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors.
